Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2020 0 · FY2021 1,150 · FY2022 568 — 3-yr total 1,718
Operates in Healthcare Services — Other healthcare services. Per the activity note to the FY2022 annual report, the company provides specialized medical practice services and pharmaceutical wholesale trade. Registered on 5 November 2018.
| Ratio | 2020 | 2021 | 2022 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 75.3% | 48.6% | 34.7% |
| EBITDA Margin | 57.9% | 32.7% | 34.0% |
| EBITDAR | 315 | 1,356 | 753 |
| EBITDAR Margin | 63.0% | 33.6% | 34.4% |
| EBIT Margin | 57.9% | 28.3% | 31.6% |
| Net Profit Margin | 56.0% | 27.8% | 31.6% |
| Operating Expense % of Sales | 64.2% | 15.9% | 0.6% |
| Returns | |||
| Return on Assets (ROA) | 22.6% | 112.7% | 183.8% |
| Return on Equity (ROE) | 100.0% | 447.6% | 185.1% |
| ROIC [EBIT / Invested Capital] | 104.0% | N/A | 188.5% |
| Leverage & debt balances | |||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 22.6% | 25.2% | 99.3% |
| Net Debt | -2 | -257 | -7 |
| Cash & Equivalents | 2 | 257 | 7 |
| Total Debt | N/A | N/A | N/A |
| Liquidity & working capital | |||
| Current Ratio | 0.85x | 0.88x | 146.37x |
| Quick Ratio | 0.36x | 0.37x | 2.65x |
| Cash Ratio | 0.00x | 0.34x | 2.65x |
| Total Current Assets | 808 | 654 | 375 |
| Total Current Liabilities | 955 | 745 | 3 |
| Inventory | 462 | 380 | 369 |
| Trade Receivables | 344 | 17 | N/A |
| Trade Payables | 934 | 745 | 3 |
| Net Working Capital | -147 | -91 | 373 |
| Net Working Capital % of Revenue | -29.5% | -2.3% | 17.1% |
| Trade Working Capital | -128 | -348 | 366 |
| Trade Working Capital % of Revenue | -25.6% | -8.6% | 16.7% |
| Change in Trade Working Capital | N/A | -220 | 713 |
| Turnover & efficiency | |||
| Inventory Turnover | 0.27x | 5.46x | 3.87x |
| Days Inventory Outstanding (DIO) | 1368.6 | 66.9 | 94.2 |
| Receivables Turnover | 1.45x | 232.50x | N/A |
| Days Sales Outstanding (DSO) | 251.7 | 1.6 | N/A |
| Payables Turnover | 0.13x | 2.78x | 556.75x |
| Days Payable Outstanding (DPO) | 2766.4 | 131.1 | 0.7 |
| Cash Conversion Cycle | -1146.1 days | -62.7 days | 93.6 days |
| Asset Turnover | 0.40x | 4.05x | 5.82x |
| Cash flow & dividends | |||
| Operating Cash Flow | -64 | 1,405 | 214 |
| Free Cash Flow (OCF − Capex proxy) | -64 | 255 | -250 |
| Cash Conversion (OCF / EBITDA) | -22.1% | 106.4% | 28.8% |
| Dividends Declared | 0 | 1,150 | 568 |
| Dividend Payout Ratio | 0.0% | 102.6% | 82.3% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →